PureTech Health operates as a clinical-stage biotechnology incubator where value creation is primarily driven by the strategic divestiture of founded entities rather than recurring commercial revenue. While the company maintains a robust liquidity position wit...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest Apr 29, 2026 | -$26.90-1286.6% vs -$1.94 | $3M+47.2% vs $2M |
Q3 2025 Aug 28, 2025 | -$1.86+8.9% vs -$2.04 | $2M-93.2% vs $27M |
Q2 2025 Apr 30, 2025 | $0.35+112.5% vs -$2.83 | $4M-86.7% vs $30M |
Q3 2024 Aug 28, 2024 | -$0.15+94.9% vs -$3.03 | $288,000-96.2% vs $8M |
PureTech Health (NASDAQ: PRTC) outlined progress across its portfolio in its 2026 half-year results call, highlighting external financings for Celea Therapeutics and Seaport Therapeutics, regulatory progress at Gallop Oncology, and a strategy centered on earlier external funding for its founded entities. Chief Executive Officer Robert Lyne said the company entered the first half with $220 million
Benchmark PRTC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for PureTech Health plc (PRTC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $17.38 | $41.95M | -0.38 | -3.5% | -2355.42% | -30.76% | — | |
| $36.82 | $26.6B | -85.63 | -71.57% | -3534.88% | -5.33% | — | |
| $7.35 | $2.72B | -2.53 | 1227.6% | -14938.37% | -353.02% | — | |
| $13.75 | $1.86B | -4.46 | — | — | -398.21% | — | |
| $3.70 | $1.94B | -2.57 | 26.92% | -945.92% | -50.41% | — | |
| $9.75 | $1.65B | -11.60 | -38.24% | -7756.37% | -59.21% | — |
PureTech Health plc (PRTC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when PRTC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PureTech Health plc (PRTC) stock FAQ — growth, dividends, profitability & financials explained
PureTech Health plc (PRTC) reported $9.0M in revenue for fiscal year 2025. This represents a 13% increase from $7.9M in 2012.
PureTech Health plc (PRTC) saw revenue decline by 3.5% over the past year.
PureTech Health plc (PRTC) reported a net loss of $56.0M for fiscal year 2025.
PureTech Health plc (PRTC) has a return on equity (ROE) of -30.8%. Negative ROE indicates the company is unprofitable.
PureTech Health plc (PRTC) had negative free cash flow of $218.8M in fiscal year 2025, likely due to heavy capital investments.
